TauRx Pharmaceuticals Ltd. is a clinical-stage biotechnology company headquartered in Aberdeen, Scotland, focused exclusively on developing tau-based therapies for Alzheimer's disease and other neurodegenerative disorders. The company is a pioneer in tau aggregation inhibitor (TAI) research, with over two decades of experience targeting the tau protein pathology that correlates strongly with cognitive decline in Alzheimer's disease[1].
Founded in 2002 as a spinout from the University of Aberdeen, TauRx has advanced the most advanced oral tau aggregation inhibitor in clinical development. The company's flagship compound, hydromethylthionine mesylate (HMTM), has demonstrated significant cognitive benefits in Phase 3 clinical trials[2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| HMTM (Hydromethylthionine mesylate) | Tau aggregation inhibitor | Alzheimer's disease | Phase 3 | Approved (UK) |
| HMTM | Tau aggregation inhibitor | Behavioral variant Frontotemporal Dementia | Phase 3 | Clinical |
| LMTM (Leu- methylthionine) | Tau aggregation inhibitor | Alzheimer's disease | Phase 3 | Completed |
| Newer TAI compounds | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research |
HMTM is a tau aggregation inhibitor that works through a unique dual mechanism:
Key Properties:
Phase 3 Results (TRx-237-007):
The pivotal Phase 3 study in approximately 500 patients with mild-to-moderate Alzheimer's disease demonstrated:
Regulatory Status:
While amyloid-beta has been the primary focus of Alzheimer's research, tau pathology correlates more strongly with cognitive decline:
The formation of toxic tau aggregates involves:
Headquarters: Aberdeen, Scotland, UK
Founded: 2002
CEO: Dr. Claude Wischik (co-founder)
Chairman: Professor Sir James Black
Key Focus Areas:
TauRx emerged from research at the University of Aberdeen led by:
| Name | Position | Background |
|---|---|---|
| Dr. Claude Wischik | CEO & Co-founder | Tau biology researcher |
| Prof. Peter St George-Hyslop | SAB Chair | Neuroscience researcher |
| Dr. Michael Wittenberg | CMO | Clinical development |